tiprankstipranks
Advertisement
Advertisement

OVID Stock Latest News

Ovid Therapeutics price target raised to $9 from $7 at Oppenheimer
The FlyOvid Therapeutics price target raised to $9 from $7 at Oppenheimer
8m ago
OVID
Ovid Therapeutics appoints Charles Carter as new CFO
PremiumCompany Announcements
Ovid Therapeutics appoints Charles Carter as new CFO
26d ago
8K
OVID
Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed
PremiumThe Fly
Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed
26d ago
OVID
Ovid Therapeutics Shareholders Back Board and Governance Proposals
PremiumCompany Announcements
Ovid Therapeutics Shareholders Back Board and Governance Proposals
2M ago
8K
OVID
Ovid Therapeutics Expands Board, Appoints New Scientific Director
PremiumCompany Announcements
Ovid Therapeutics Expands Board, Appoints New Scientific Director
2M ago
8K
OVID
Ovid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price Target
PremiumRatingsOvid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price Target
2M ago
OVID
Ovid Therapeutics price target raised to $7 from $5 at Roth Capital
Premium
The Fly
Ovid Therapeutics price target raised to $7 from $5 at Roth Capital
3M ago
OVID
Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)
Premium
The Fly
Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)
3M ago
OVID
OVID Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OVID Earnings this Week: How Will it Perform?
3M ago
OVID
Ovid Therapeutics files to sell 29.86M shares of common stock for holders
PremiumThe Fly
Ovid Therapeutics files to sell 29.86M shares of common stock for holders
3M ago
OVID
Ovid Therapeutics Boosts Capital Through Warrant Exercises
PremiumCompany Announcements
Ovid Therapeutics Boosts Capital Through Warrant Exercises
3M ago
8K
OVID
Ovid Therapeutics: Differentiated KCC2 ‘Master Switch’ Platform and Strong Cash Runway Underpin Buy Rating
PremiumRatings
Ovid Therapeutics: Differentiated KCC2 ‘Master Switch’ Platform and Strong Cash Runway Underpin Buy Rating
4M ago
OVID
Ovid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy Rating
PremiumRatingsOvid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy Rating
4M ago
OVID
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
Premium
The Fly
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
4M ago
OVID
3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts
4M ago
IVA
OVID
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
PremiumThe Fly
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
5M ago
OVID
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
PremiumCompany Announcements
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
5M ago
OVID
Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
PremiumThe Fly
Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
5M ago
OVID
Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating
PremiumRatings
Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating
5M ago
OVID
Midday Fly By: General Mills reports downbeat Q3, Macy’s reports Q4 beat
PremiumThe FlyMidday Fly By: General Mills reports downbeat Q3, Macy’s reports Q4 beat
5M ago
M
CF
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention
Premium
TipRanks Newswire
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention
5M ago
CING
OVID
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline
Premium
Company Announcements
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline
5M ago
8K
OVID

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >